National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$37.00
add to cart

Rights & Permissions

topleft topright

The Anthrax Vaccine: Is It Safe? Does It Work? (2002)
Institute of Medicine (IOM)

Citation Manager

. "Appendix A Statement of Task." The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press, 2002.

Please select a format:

BibTeX EndNote RefMan


Page
211
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


The Anthrax Vaccine: Is it Safe? Does it Work?

Appendixes

Page
211

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 211
The Anthrax Vaccine: Is it Safe? Does it Work? Appendixes

OCR for page 212
The Anthrax Vaccine: Is it Safe? Does it Work? This page in the original is blank.

OCR for page 213
The Anthrax Vaccine: Is it Safe? Does it Work? Appendix A Statement of Task The committee will analyze available information, hold workshops, and make specific recommendations on technical aspects regarding the safety and efficacy of the licensed anthrax vaccine. The issues include the types and severity of adverse reactions, including gender (sex) differences; long-term health implications; inhalational efficacy of the vaccine against all known anthrax strains; correlation of animal models to safety and effectiveness in humans; validation of the manufacturing process focusing on, but not limited to, discrepancies identified by the Food and Drug Administration in February 1998; definition of vaccine components in terms of the protective antigen and other bacterial products and constituents; and identification of gaps in existing research.

Representative terms from entire chapter:

aspects regarding